Drugs / SSS67
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07487545 | Mar → Aug 2026 overdue | — | Shenyang Sunshine Pharmaceutical Co., LTD. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SSS67 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07487545 ↗ |
| Route | Intravenous | “SSS67 Injection will be administered via intravenous infusion.” NCT07487545 ↗ |